Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice (AMBER)
Retrospective Observational Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice
This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. The study will be conducted by reviewing the medical records of patients up to the start of the study. In each case, only data from before the start of the study will be obtained in order to ensure they are retrospective in nature, thus reflecting the regular use of nab-paclitaxel in clinical practice and avoiding interference with the physician's clinical practice.
To ensure the observational nature of this study, these data will be collected whenever they are available in the patient's medical record, and so no diagnostic or therapeutic intervention outside regular clinical practice will be used.
연구 개요
상태
정황
상세 설명
This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. Investigators will include all consecutive adult patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014). These patients must meet all the inclusion criteria and none of the exclusion criteria established in this protocol.
The primary objective is to describe the effectiveness of nab-paclitaxel in terms of response in early lines of chemotherapy for metastatic breast cancer in routine clinical practice.
This study plans to collect data retrospectively, provided they are available in the patient's medical record and according to routine clinical practice.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Madrid, 스페인, 28040
- Hospital Clínico San Carlos
-
Madrid, 스페인, 28033
- MD Anderson
-
Madrid, 스페인, 28041
- Hospital 12 Octubre
-
Madrid, 스페인, 28007:
- Hospital Gregorio Marañon
-
Madrid, 스페인, 28223
- Hospital Quirón
-
Murcia, 스페인, 30008
- Hospital Morales Meseguer
-
-
Andalucía
-
Jaén, Andalucía, 스페인, 23007
- Complejo Hospitalario Jaén
-
-
Aragón
-
Zaragoza, Aragón, 스페인, 50009
- Hospital Clinico Lozano Blesa
-
-
Castilla La Mancha
-
Toledo, Castilla La Mancha, 스페인, 45071
- Hospital Virgen Salud
-
-
Castilla y León
-
Burgos, Castilla y León, 스페인, 09006
- Hospital Universitario Burgos
-
Salamanca, Castilla y León, 스페인, 37007
- Hospital Clinico Salamanca
-
Valladolid, Castilla y León, 스페인, 47005:
- Hospital Clínico Valladolid
-
-
Cataluña
-
Barcelona, Cataluña, 스페인, 08035
- Hospital Vall D´Hebron
-
Reus, Cataluña, 스페인, 43204
- Hospital Universitario San Joan Reus
-
-
Extremadura
-
Badajoz, Extremadura, 스페인, 06006
- Hospital Infanta Cristina
-
Badajoz, Extremadura, 스페인, 06011
- Capio Clideba
-
-
Galicia
-
Orense, Galicia, 스페인, 32005
- Complejo Hospitalario Orense
-
-
Murcia
-
Cartagena, Murcia, 스페인, 30202
- Hospital Santa Lucía
-
-
Navarra
-
Pamplona, Navarra, 스페인, 31008
- Hospital Navarra
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Women ≥18 years of age.
- Confirmed diagnosis of MBC (stage IV).
- Breast adenocarcinoma confirmed histologically.
- HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.
- Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.
- Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).
Exclusion Criteria:
- Patients with any medical or psychological disorder which in the investigator's opinion might compromise the ability of the patient to give their informed consent.
- Patients who have received treatment with nab-paclitaxel combined with other chemotherapy agents or anti-angiogenic drugs or tumor-targeting drugs with anti-tumor activity.
- Patients who have taken part in any clinical trial (interventional) during the study period.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
Abraxane® treatment in patients with metastatic breast cancer
Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall response rate (ORR)
기간: Up to approximately 8 months
|
The number of patients who achieve a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria during treatment with nab-paclitaxel until disease progression, the end of treatment or the start of the study, whichever comes first.
|
Up to approximately 8 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Response Rate (ORR)
기간: Up to approximately 8 months
|
The number of patients who achieve a complete response (CR) or partial response (PR) during the first 3 treatment cycles with nab-paclitaxel and the corresponding 95% CI will be calculated.
|
Up to approximately 8 months
|
|
Disease control rate (DCR)
기간: Up to approximately 8 months
|
The percentage of patients with complete response (CR), partial response (PR), or stable disease (SD) for at least 16 weeks, and the corresponding 95% confidence intervals (CI) will be calculated.
|
Up to approximately 8 months
|
|
Time to disease progression (TTP)
기간: Up to approximately 8 months
|
Is defined as the time from the start of treatment with nab-paclitaxel to disease progression or death due to progression.
TTP will be estimated by using the Kaplan-Meier method.
The median and confidence interval for the median at 95% reliability (95% CI) will be calculated.
In patients who show no disease progression or who have not died, the date of censoring may be the day on which the patient's death is documented, the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
|
Up to approximately 8 months
|
|
Progression-free survival (PFS)
기간: Up to approximately 8 months
|
Is defined as the time from the start of treatment with nab-paclitaxel to disease progression or death from any cause.
PFS will be estimated by using the Kaplan-Meier method.
Patients who have shown no disease progression or who have not died at the time of data collection will be censored on the date on which it was last known that no disease progression occurred.
The date of censoring may be the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
|
Up to approximately 8 months
|
|
Overall survival (OS)
기간: Up to approximately 8 months
|
Is defined as the time from the start of treatment with nab-paclitaxel to death from any cause.
OS will be estimated by using the Kaplan-Meier method.
Patients who have not died at the time of data collection will be censored on the date on which they are last known to be alive.
The date of censoring may be the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
|
Up to approximately 8 months
|
|
Adverse Events (AEs)
기간: Up to approximately 8 months
|
Number of participants with adverse events
|
Up to approximately 8 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Lorena Pellín, MD, Celgene Spain
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .